| Literature DB >> 31582259 |
Maria Anna Smolle1, Felix Prinz2, George Adrian Calin3, Martin Pichler4.
Abstract
The discovery of immune checkpoint molecules as important regulators of immune responses in healthy individuals as well as immune escape of malignant tumours has led to profound changes in understanding, research and treatment of human cancer. Especially the introduction of immune checkpoint inhibitors in cancer therapy has set anti-cancer therapy on a novel level. With increasing experience of approved CTLA-4 and PD1/PD-L1 inhibitors and the evolution of novel immune checkpoint molecules from pre-clinical models to clinical trials, mechanisms of the regulation of these immune system guiding factors, are of paramount importance to overcome mechanisms of resistance. Non-protein coding RNAs (i.e. non-coding RNAs) such as short microRNAs and long non-coding RNAs are involved in regulating of various cellular processes and have attracted attention of cancer researchers and immunologists over the last years. In the present review, interactions between non coding RNAs and immune checkpoint molecules, within the framework of human cancer, will be discussed and current and developing concepts between the immunological and non-coding RNA world, will be elucidated.Entities:
Keywords: Cancer; Immune checkpoint molecule; Non-coding RNA
Mesh:
Substances:
Year: 2019 PMID: 31582259 DOI: 10.1016/j.mam.2019.09.007
Source DB: PubMed Journal: Mol Aspects Med ISSN: 0098-2997